We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.39M
AUM Growth
-$132K
Cap. Flow
+$358M
Cap. Flow %
6,649.45%
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$104M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$90.6M
3
TMO icon
Thermo Fisher Scientific
TMO
+$49.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.8M
5
BLU
BELLUS Health Inc.
BLU
+$33.8M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$81.3M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$44.9M
3
ABBV icon
AbbVie
ABBV
+$28.7M
4
VTYX
Ventyx Biosciences
VTYX
+$23.6M
5
PCVX icon
Vaxcyte
PCVX
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
$341K 6.32%
2,718,735
– –
BMY icon
2
Bristol-Myers Squibb
BMY
$130B
$184K 3.41%
2,584,900
+66,200
+3% +$4.8M
HUM icon
3
Humana
HUM
$43.4B
$169K 3.14%
348,700
-17,000
-5% -$8.27M
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$158K 2.93%
5,525,926
-502,381
-8% -$14.4M
BSX icon
5
Boston Scientific
BSX
$68.3B
$151K 2.8%
3,898,200
-471,300
-11% -$18.9M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$146K 2.7%
1,717,310
+17,600
+1% +$1.57M
EWTX icon
7
Edgewise Therapeutics
EWTX
$4.33B
$143K 2.66%
14,567,176
+484,496
+3% +$4.9M
UNH icon
8
UnitedHealth
UNH
$387B
$135K 2.51%
267,200
-14,000
-5% -$7.36M
PFE icon
9
Pfizer
PFE
$144B
$114K 2.11%
2,599,000
-145,000
-5% -$7.05M
THRD
10
DELISTED
Third Harmonic Bio
THRD
$110K 2.04%
+5,779,071
New +$104M
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$125B
$108K 2.01%
373,200
-14,000
-4% -$4.03M
TCDA
12
DELISTED
Tricida, Inc. Common Stock
TCDA
$108K 2%
10,280,947
– –
ISRG icon
13
Intuitive Surgical
ISRG
$128B
$107K 1.99%
572,700
+55,500
+11% +$11.9M
ACET icon
14
Adicet Bio
ACET
$76.7M
$106K 1.97%
465,446
– –
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
$104K 1.94%
762,600
+75,100
+11% +$12.2M
TMO icon
16
Thermo Fisher Scientific
TMO
$215B
$103K 1.9%
202,200
+88,800
+78% +$49.7M
SRPT icon
17
Sarepta Therapeutics
SRPT
$1.61B
$102K 1.88%
918,500
+898,500
+4,493% +$90.6M
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$99.1K 1.84%
1,418,892
+328,492
+30% +$24.3M
THRX
19
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$98.8K 1.83%
17,041,668
– –
NBIX icon
20
Neurocrine Biosciences
NBIX
$18.2B
$95.2K 1.77%
896,545
+47,000
+6% +$4.77M
ARGX icon
21
argenx
ARGX
$55.1B
$95.2K 1.77%
269,700
+75,700
+39% +$28M
SYK icon
22
Stryker
SYK
$134B
$85.7K 1.59%
423,100
-18,000
-4% -$3.79M
ABBV icon
23
AbbVie
ABBV
$469B
$80.5K 1.49%
600,000
-199,800
-25% -$28.7M
EW icon
24
Edwards Lifesciences
EW
$48.5B
$79.8K 1.48%
966,300
-45,000
-4% -$4.33M
PMVP icon
25
PMV Pharmaceuticals
PMVP
$58.7M
$78.1K 1.45%
6,563,077
– –
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2022 Portfolio in Review

As of Q3 2022, OrbiMed held 156 positions worth $5.39M, down 2.4% from $5.52M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed deployed $358M of net new capital in Q3 2022, opening 15 new positions and adding to 31 existing holdings. Its largest new stake was Third Harmonic Bio: 5,779,071 shares worth $110K.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $81.3M trimmed.

  • OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110K.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
  • OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
  • OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168K.
  • OrbiMed's ten largest holdings make up 31% of its $5.39M portfolio in Q3 2022.
  • OrbiMed opened 15 new positions and closed 25 in Q3 2022.
  • OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39M.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.